Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

@article{Wong2004ChronicTW,
  title={Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.},
  author={Gwendolyn T. Wong and Denise Manfra and Frederique M. Poulet and Qi Zhang and Hubert Josien and Thomas A Bara and Laura Engstrom and M Consuelo Pinzon-Ortiz and Jay S. Fine and Hu-Jung J. Lee and Lili Zhang and Guy A Higgins and Eric M. Parker},
  journal={The Journal of biological chemistry},
  year={2004},
  volume={279 13},
  pages={12876-82}
}
Inhibition of gamma-secretase, one of the enzymes responsible for the cleavage of the amyloid precursor protein (APP) to produce the pathogenic beta-amyloid (Abeta) peptides, is an attractive approach to the treatment of Alzheimer disease. In addition to APP, however, several other gamma-secretase substrates have been identified (e.g. Notch), and altered processing of these substrates by gamma-secretase inhibitors could lead to unintended biological consequences. To study the in vivo… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 187 extracted citations

Similar Papers

Loading similar papers…